Skip to content

Early Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke

Early Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke - a Randomized Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07232498
Acronym
DOP-MOBILIZE
Enrollment
1300
Registered
2025-11-18
Start date
2025-06-04
Completion date
2027-12-01
Last updated
2026-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Ischemic Stroke

Keywords

Arterial Ischemic Stroke, Early mobilization, mRS, Transcranial doppler ultrasound, Neurology, Hemodynamics

Brief summary

Post-stroke mobilization remains a subject of ongoing debate. While early mobilization-particularly the first out-of-bed mobilization-has been associated with reduced systemic complications and earlier rehabilitation, it also carries potential risks, such as neurological deterioration in the presence of hemodynamic instability. In this study, the primary aim is to investigate whether early mobilization, guided by hemodynamic evaluation after acute ischemic stroke offers superior outcomes compared to standard clinical care.

Detailed description

Cerebrovascular diseases are the leading cause of death in Portugal and one of the most significant contributors to morbidity and disability. Early mobilization after stroke is debated due to its potential benefits-such as fewer systemic complications and faster rehabilitation-and risks, particularly in patients with hemodynamic instability. International guidelines support for early mobilization tailored to the patient's neurological status; however, the scientific evidence remains limited, resulting in heterogeneous practices across institutions. Previous studies have highlighted the insufficient consideration of hemodynamic status when determining the timing of initial mobilization. This study is a phase 3, pragmatic, prospective, multicenter randomized controlled trial with blinded outcome assessment (PROBE design: Prospective, Randomized, Open-label, Blinded Outcome Assessment), with an anticipated total duration of 36 months. The study will be conducted in the Neurology Departments of the participating hospital centers and aims to: (1) evaluate the superiority of early mobilization guided by hemodynamic assessment following acute ischemic stroke, compared to standard clinical practice; (2) assess neurological deficits, quality of life, and cognitive function at three months, as well as hospital length of stay, blood pressure profile evolution, patient-reported outcome measures (PROMs), and employability; (3) compare adverse events between patients undergoing Doppler-guided early mobilization and those in the control group, including hospital-acquired infections, neurological deterioration, hemorrhagic transformation, and mortality. Patients randomized to the intervention group will be mobilized according to carotid and transcranial Doppler ultrasound findings. In the presence of hemodynamic impairment, patients will undergo progressive mobilization, aiming to be out of bed by days 5 to 7 post-stroke, with gait training as neurologically feasible. In the absence of such findings, patients will begin mobilization immediately after the examination, with the goal of being out of bed and seated within 48 hours, including gait training when possible. Functional status at three months will be assessed using the modified Rankin Scale (mRS), which constitutes the study's primary endpoint. All data collection procedures will follow formal and ethical research standards, ensuring that all informed participants voluntarily, anonymously, consent to take part in the study, with confidentiality maintained and no costs or harm to participants.

Interventions

PROCEDUREDoppler-guided early mobilization

Individualized early mobilization after ischemic stroke, guided by hemodynamic assessment using carotid and transcranial Doppler ultrasound. The type and timing of mobilization are adjusted according to the presence of significant hemodynamic alterations.

Sponsors

Unidade Local de Saúde de Coimbra, EPE
Lead SponsorOTHER
Unidade Local de Saúde São João
CollaboratorOTHER_GOV
Unidade Local de Saúde Santa Maria
CollaboratorOTHER_GOV
Unidade Local de Saúde de Matosinhos, EPE
CollaboratorOTHER
University Hospital Rijeka
CollaboratorOTHER
Unidade Local de Saúde de São José
CollaboratorINDIV
Klinički Bolnički Centar Zagreb
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with ischemic stroke aged 18 years or older; * Ability to undergo carotid and transcranial Doppler ultrasound, as well as to mobilize within 48 hours; * Informed consent obtained from the patient or legal representative.

Exclusion criteria

* Pre-existing disability with a modified Rankin Scale (mRS) score ≥ 4; * Diagnosis of Transient Ischemic Attack (TIA); * Severe hemodynamic instability, defined as: * Systolic blood pressure \< 100 mmHg or \> 220 mmHg; * Peripheral oxygen saturation \< 92%; * Heart rate \< 40 or \> 112 beats per minute; * Body temperature \> 38.5°C; * Neurological deterioration with altered level of consciousness (defined as Glasgow Coma Scale \< 10); * Patients who underwent neurosurgical intervention within the past 30 days; * Concomitant diagnosis of a rapidly progressive fatal disease (e.g., terminal-stage cancer); * Requirement for continuous monitoring or continuous intravenous drug infusion; * Acute deep vein thrombosis/pulmonary embolism.

Design outcomes

Primary

MeasureTime frameDescription
Functional status at 3 months after ischemic stroke3 months post-strokeFunctional status assessment at 3 months after ischemic stroke, using the modified Rankin Scale (mRS), analyzed on an ordinal scale (0-6), to measure the degree of dependence/functional impairment. Score ranges: 0-no residual symptoms (better outcome); 1. no significant disability; 2. slight disability; 3. moderate disability; 4. moderately severe disability; 5. severe disability; 6. death (worse outcome).

Secondary

MeasureTime frameDescription
Neurological Assessment (NIHSS Scale)Day 0, 48 hours, Day 7 and Month 3Neurological assessment on the 7th day after ischemic stroke, measured using the National Institutes of Health Stroke Scale score (NIHSS, from 0-42) to evaluate the severity of neurological deficits. Score ranges: 0-4: Minor Stroke (better outcome); 5-15: Moderate Stroke; 16-20: Moderate to Severe Stroke; 21-42: Severe Stroke (worse outcome).
Development of hospital-acquired infectionsUp to 7 daysIncidence of infections acquired during hospitalization
Vital signs - Body temperatureDay 0, 48 hours, Day 7Measurement of body temperature in degrees Celsius at the time of the visit
Vital signs - Systolic and diastolic blood pressureDay 0, 48 hours, Day 7Measurement of blood pressure in mmHg at the time of the visit
Vital signs - Heart rateDay 0, 48 hours, Day 7Measurement of heart rate in beats per minute (bpm) at the time of the visit
Mortality3 monthsMortality rate (%)
EQ-5D-5L3 monthsAn instrument to describe and value health across a wide range of disease areas. 5-level EQ-5D (EuroQol instrument with 5 dimensions and 5 levels) version with five dimensions (five levels, categorical options): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Score ranges: 1. I have no problems ...walking/dressing, etc (better outcome); 2. I have some problems ...walking/dressing, etc; 3. I have moderate problems ...walking/dressing, etc; 4. I have severe problems ...walking/dressing, etc; 5. I have extreme problems ...walking/dressing, etc (worse outcome).
Recurrent stroke assessmentDay 0, 48 hours, Day 7Assessment of stroke recurrence after the first event, specifying the type into categories (no recurrence, new transient ischemic attack, new ischemic stroke, hemorrhagic stroke) and the time interval between events.
MONTREAL COGNITIVE ASSESSMENT (MoCA)Month 3A brief cognitive screening tool used to assess mild cognitive impairment, score from 0-30. Score ranges: \< 19: moderate to severe cognitive impairment (worse outcome); 19-25: mild cognitive impairment; \> 26: normal (better outcome).
Hospital Anxiety and Depression Scale (HADS)3 monthsFinal score of the scale that assesses anxiety and depression in patients, especially those with physical illnesses (score from 0-21, wiht 14 items and each item with four-point scale, 0-3). Score ranges: 0-7: Normal - No significant symptoms of anxiety or depression (better outcome); 8-10: Borderline/Mild - Presence of symptoms that may require attention; 11 or higher: Probable Case/Severe - Clinically significan psychological disorder or "probable case" (worse outcome).
Mobility assessment48 hours, Day 7, Month 3.Assessment of participant mobility according to categories (not yet mobilized, transfers to chair, ambulating)
Breath Holding Index (BHI) - measure 1Before 48 hours or Day 7 (if not performed previously)Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels. Three attempts will be performed for each participant with measurements of: * (a) baseline mean flow velocity before the apnea test (cm/sec)
Breath Holding Index (BHI) - measure 2Before 48 hours or Day 7 (if not performed previously)Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels. Three attempts will be performed for each participant with measurements of: * (b) mean flow velocity at the end of the apnea test (cm/sec).
Breath Holding Index (BHI) - measure 3Before 48 hours or Day 7 (if not performed previously)Non-invasive method used to assess cerebrovascular reactivity, specifically the ability of the brain's blood vessels to adjust to changes in carbon dioxide levels. Three attempts will be performed for each participant with measurements of: * (c) apnea duration (sec).
Hemorrhagic transformation48 hours, Day 7Type of ischemic stroke complication according to hemorrhage infarction (HI) /parenchymal hemorrhage (PH) levels in brain tissue. Score: 0- No complication HI1- Hemorrhage infarction 1; HI2- Hemorrhage infarction 2; PH1- Parenchymal hemorrhage 1; PH2- Parenchymal hemorrhage 2; No follow-up CT/MRI performed.
Early Mobilization Decision (<48h)Day 0Ultrasound-guided (US) mobilization: early mobilization (\<48h) if no cerebral hemodynamic impairment in US; Decision - yes or no? (only for interventional group)
Hospitalization durationMonth 3Number of days of hospitalization
White matter lesions in neuroimagingDay 0White matter legions in neuroimaging - ARWMC scale: 0-no lesions (better outcome); 1-focal lesions; 2-beginning confluence of lesions; 3-diffuse involvement of the entire region, with or without involvement of U fibers (worse outcome).

Countries

Portugal

Contacts

CONTACTJoao Sargento Freitas, MD, PhD
joaosargentofreitas@ulscoimbra.min-saude.pt+351 239 400 400
CONTACTClinical Trials Unit - Coimbra Academic Clinical Center CTU-CACC Unidade Local de Saude de Coimbra
ctu-cacc@ulscoimbra.min-saude.pt+351 239 400 400
PRINCIPAL_INVESTIGATORJoao Sargento Freitas, MD, PhD

Unidade Local de Saude de Coimbra

STUDY_DIRECTORJoao Sargento Freitas, MD, PhD

Unidade Local de Saude de Coimbra

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 26, 2026